Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene expression profiling: will it complement or replace immunophenotyping?

Adolfo A Ferrando1, A Thomas Look

  • 1Pediatric Oncology Department, Harvard Medical School, Vice-Chair of Research, Mayer 630, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA. adolfo_ferrando@dfci.harvard.edu

Best Practice & Research. Clinical Haematology
|November 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reactivation of a TAL1 progenitor cell enhancer region by non-coding somatic variants in T-lineage acute lymphoblastic leukemia.

bioRxiv : the preprint server for biology·2026
Same author

Transcription factor cooperativity at a GATA3 tandem DNA sequence determines oncogenic enhancer-mediated activation.

Cell reports·2026
Same author

Multitargeted Reduction of Inflammation and Atherosclerosis in <i>Tet2</i> -deficient CHIP via XPO1 Inhibition and Atf3 restoration.

bioRxiv : the preprint server for biology·2025
Same author

KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma.

bioRxiv : the preprint server for biology·2025
Same author

Transcription factor cooperativity at a GATA3 tandem DNA sequence determines oncogenic enhancer-mediated activation.

Cell reports·2025
Same author

Therapeutic targeting of the NOTCH1 and neddylation pathways in T cell acute lymphoblastic leukemia.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Gene expression profiling and immunophenotyping are key for diagnosing blood cancers. This review explores if DNA microarrays will replace or complement current flow cytometry methods for improved leukemia and lymphoma diagnosis and therapy.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Gene expression profiling using DNA microarrays offers genome-wide RNA analysis for hematological malignancies.
  • Flow cytometry analysis of surface antigens is crucial for diagnosing leukemia and lymphoma, guiding therapy.
  • The rapid advancement of microarray technology raises questions about its role alongside immunophenotyping.

Purpose of the Study:

  • To compare DNA microarray gene expression profiling with flow cytometric immunophenotyping in diagnosing hematological malignancies.
  • To assess the technical advantages, pitfalls, and synergistic potential of these two diagnostic approaches.
  • To determine if gene expression profiling will replace or complement immunophenotyping in improving leukemia and lymphoma diagnosis and therapy.

Main Methods:

Related Experiment Videos

  • Review of technical aspects of DNA microarray gene expression profiling.
  • Review of technical aspects of flow cytometric immunophenotyping.
  • Comparative analysis of the two methodologies.

Main Results:

  • DNA microarrays provide genome-wide expression data, aiding in the molecular classification of cancers.
  • Flow cytometry offers cell surface marker information essential for identifying cell lineage and differentiation.
  • Both methods have distinct advantages and limitations, with potential for complementary use.

Conclusions:

  • Gene expression profiling and immunophenotyping are currently complementary, not interchangeable, in hematological malignancy diagnosis.
  • The integration of both technologies holds promise for more accurate diagnosis and personalized therapeutic strategies.
  • Further research is needed to fully elucidate the synergistic applications of these powerful diagnostic tools.